US Patent

US10639309 — Tofacitinib oral sustained release dosage forms

Formulation · Assigned to Pfizer Inc · Expires 2034-03-14 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects oral sustained release formulations of tofacitinib and its pharmaceutical acceptable salts.

USPTO Abstract

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

Drugs covered by this patent

Patent Metadata

Patent number
US10639309
Jurisdiction
US
Classification
Formulation
Expires
2034-03-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.